Devicor Medical Germany GmbHNordport Towers, Südportal 3
22848 Norderstedt, Germany
- Telefon: +49 (040) 59355910
- Wir suchen:
- Wir suchen derzeit eine/ einen Aussendienstmitarbeiter/ in für die Region Hessen. Bei Interesse melden Sie sich bitte unter email@example.com .
- Wir bieten:
- Mammotome currently employs 300 people with offices in the following countries: • United States • Mexico • France • Germany • Italy • United Kingdom • China • Hong Kong • Japan • Korea
- Art des Unternehmens:
Devicor™ Medical Products, Inc., parent company of Mammotome, is dedicated to building a global business through the investment in and development of tools and technologies that facilitate minimally invasive medical procedures. For more information, please visit www.devicormedical.com.
Mammotome, a Devicor Medical Company
Mammotome is the global leader of vacuum-assisted breast biopsy products and is committed to developing and providing products that help doctors diagnose breast disease through minimally invasive procedures. Since 1995, more than 3.4 million women worldwide have had an image-guided minimally invasive breast biopsy using the Mammotome® Biopsy System.
The Mammotome product portfolio includes the Mammotome® Biopsy System and tissue markers, MammoMARK™, MicroMARK® and CorMARK™. Mammotome® products are sold in more than 50 countries around the world. Devicor™ Medical Products, Inc. recently aquired Neoprobe® Gamma Detection Systems.
Mammotome is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures.
As the global market leader in vacuum-assisted breast biopsy, Mammotome has offered physicians and women a wide range of options and diagnostic tools since 1995.
The Mammotome® Biopsy System is a complete system for breast tissue sampling and management. Compatible with multiple imaging modalities, the Mammotome® Biopsy System enables breast biopsy to be performed under stereotactic x-ray, ultrasound, MRI or molecular imaging guidance. Mammotome offers a full array of tissue markers to mark the biopsy site for follow-up observations. With the Mammotome® Biopsy System, clinicians can achieve diagnostic confidence using a less invasive approach that offers women faster recovery, less scarring and lower costs of care as compared to open procedures.
More than 3 million women worldwide have had an image-guided, minimally invasive breast biopsy using the Mammotome® Biopsy System. More physicians have relied on Mammotome to help them reach the proper diagnosis and treatment for their patients. And, more women's lives – and the people who love them – have been enhanced with an accurate diagnosis. Which is, ultimately, the point.